Simulation of clinical trials: a review with emphasis on the design issues
AbstractSimulation is a widely used tool to investigate real-world systems in a large number of fields, including clinical trials for drug development, since real trials are costly, frequently fail and may lead to serious side effects. This paper is a survey of the statistical issues arising in these simulated trials, with particular emphasis on the design of such virtual experiments, stressing similarities and differences with the design of real trials. We discuss the aims and peculiarities of the simulation models used in this context, including a brief mention of metamodels, and different validating techniques. We illustrate each specific issue through one or more studies recently reported in the medical and/or pharmaceutical literature. We end the paper with some challenging questions on the scientific rigour, ethics and effectiveness of simulation in clinical research, and the interesting research problem of how to integrate virtual and physical experiments in a clinical context.
I. ABBAS, J. ROVINA, J. CASANOVAS (2006), Validation by simulation of a clinical trial model using the standardized mean and variance criteria, “Journal of Biomedical Informatics”, 39, pp. 687-696.
I. ABBAS, J. ROVIRA, J. CASANOVAS, T. GREENFIELD (2008), Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients, “Journal of Biomedical Informatics”, 41, pp. 1053-1061.
S. ALBERS, B. MEIBOHM, T.S. MIR, S. LÄER (2007), Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure, “British Journal of Clinical Pharmacology”, 65, pp. 511-522.
A.C. ATKINSON, A.N. DONEV, R.D. TOBIAS (2007), Optimum Experimental Designs, With Sas, Oxford University Press, Oxford; New York.
A. BALDI ANTOGNINI, P. BORTOT, A. GIOVAGNOLI (2008), Randomized Group Up and Down Experiments, “Annals of the Institute of Statistical Mathematics”, 60, pp. 45-59.
A. BALDI ANTOGNINI, A. GIOVAGNOLI (2004), A new ‘biased coin design’ for the sequential allocation of two treatments, “Journal of the Royal Statistical Society”, Series B, 53, pp. 651-664.
A. BALDI ANTOGNINI, M. ZAGORAIOU (2010), Exact optimal designs for Computer Experiments via Kriging metamodeling, “Journal of Statistical Planning and Inference”, 140, pp. 2607-2617.
S. CHABAUD, P. GIRARD, P. NONY, J.P. BOISSEL (2002), Clinical trial simulation using therapeutic effect modeling: Application to ivabradine efficacy in patients with angina pectoris, “Journal of Pharmacokinetics and Pharmacodynamics”, 29, pp. 339-363.
P.L. CHAN, J.G. NUTT, N.H. HOLFORD (2007), Levodopa slows progression of Parkinson’s disease: external validation by clinical trial simulation, “Pharmaceutical Research”, 24, pp. 791-802.
L. CUI, H.M.J. HUNG, S-J. WANG (1999), Modification of Sample Size in Group Sequential Clinical Trials, “Biometrics“, 55, pp. 853-857.
D.Z. D’ARGENIO, A. SCHUMITZKY, X. WANG (2009), ADAPT 5 User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles.
A. DEAN, S. LEWIS (eds.), (2006), Screening Methods for Experimentation in Industry, Drug Discovery, and Genetics, Springer, New York.
F. DE RIDDER (2005), Predicting the Outcome of Phase III Trials using Phase II Data: A Case Study of Clinical Trial Simulation in Late Stage Drug Development, “Basic & Clinical Pharmacology & Toxicology”, 96, pp. 235-41.
G.L. DICKINSON, S. REZAEE, N.J. PROCTOR, M.S. LENNARD, G.T. TUCKER (2007), Rostami-Hodjegan A. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application, “Journal of Clinical Pharmacology”, 47, pp. 175-186.
S.B. DUFFULL, S. CHABAUD, P. NONY, C. LAVEILLE, P. GIRARD, L. AARONS (2000), A pharmacokinetic simulation model for ivabradine in healthy volunteers, “European Journal of Pharmaceutical Sciences”, 10, pp. 285-294.
D.M. EDDY, L. SCHLESSINGER (2003), Validation of the Archimedes Diabetes Model, “Diabetes Care”, 26, pp. 3102-3110.
B. EFRON (1971), Forcing sequential experiments to be balanced, “Biometrika”, 58, pp. 403-417.
K.T. FANG, R. LI, A. SUDJIANTO (2005), Design and Modeling for Computer Experiments. Chapman and Hall/CRC, London.
V. FEDOROV, R. GAGNON, S. LEONOV, Y. WU (2007), Optimal design of experiments in pharmaceutical applications, in A. Dmitrienko, C. Chuang-Stein, R. D’Agostino (eds), Pharmaceutical Statistics using SAS. A Practical Guide, SAS Press, Cary, NC, pp. 151-195.
L.M. FRIEDMAN, C.D. FURBERG, D.L. DEMETS (2010), Fundamentals of Clinical Trials, 4th Edition, Springer Verlag, New York.
A. GIOVAGNOLI, A.C. ATKINSON, B. TORSNEY (eds.), C. MAY (co-editor) (2010), mODa 9 – Advances in Model-Oriented Design and Analysis, Springer-Verlag, Berlin Heidelberg.
P. GIRARD (2005), Clinical Trial Simulation: a tool for understanding study failures and preventing them, “Basic & Clinical Pharmacology & Toxicology”, 96, pp. 228-234.
P. GIRARD, T.F. BLASCHKE, H. KASTRISSIOS, L.B. SHEINER (1998), A Markov mixed effect regression model for drug compliance, “Statistics in Medicine”, 17, pp. 2313-2334.
B. GRUWEZ, M-F. POIRIER, A. DAUPHIN, J-P. OLIÉ, M. TOD (2007), A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: Application to clomipramine-lithium interaction, “Contemporary Clinical Trials”, 28, pp. 276-287.
N.H.G. HOLFORD, M. HALE, H.C. KO, J-L. STEIMER, L.B. SHEINER, C.C. PECK (eds.) (1999) Simulation in Drug Development: Good Practices. Available at http://bts.ucsf.edu/cdds/research/sddgpreport.php. Last accessed 29 February 2012.
N. HOLFORD, S.C. MA, B.A. PLOEGER (2010), Clinical Trial Simulation: A Review, “Clinical Pharmacology & Therapeutics”, 88, pp. 166-182.
N.G.H. HOLFORD, H.C. KIMKO, J.P.R. MONTELONE, C.C. PECK (2002), Simulation of clinical trials, “Annual Review of Pharmacology and Toxicology”, 40, pp. 209-234.
F. HU, W.F. ROSENBERGER (2006), The Theory of Response-Adaptive Randomization in Clinical Trials, Wiley & Sons, New York.
H.C. KIMKO, S.B. DUFFULL (eds.) (2003) Simulation for designing clinical trials. A pharmacokineticpharmacodynamic modeling perspective, Marcel Dekker, New York.
K.G. KOWALSKI, M.M. HUTMACHER (2001), Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study, “Statistics in Medicine”, 20, pp. 75-91.
A. KRAUSE (2010), The Virtual Patient: Developing Drugs Using Modeling and Simulation, “Chance”, 23, pp. 48-52.
H. KUNITOH, K. WATANABE, T. ONOSHI, K. FURUSE, H. NIITANI, T. TAGUCHI (1996), Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study, “Journal of Clinical Oncology”, 14, pp. 1649-1655.
B.Y. LEE, S.T. BROWN, P.C. COOLEY, R.K. ZIMMERMAN, W.D. WHEATON, S.M. ZIMMER, J.J. GREFENSTETTE,
T. ASSI, T.J. FURPHY, D.K. WAGENER, D.S. BURKE (2010), A Computer Simulation of Employee Vaccination to Mitigate an Influenza Epidemic, “American Journal of Preventive Medicine”, 38, pp. 247-257.
S. LEVY, D.M. STEINBERG (2010). Computer experiments: a review. “Advances in Statistical Analysis”, 94, pp. 311-324.
P.A. LOCKWOOD, J.A. COOK, W.E. EWY, J.W. MANDEMA (2003), The use of clinical trial simulation to support dose selection: Application to development of a new treatment for chronic neuropathic pain, “Pharmaceutical Research”, 20, pp. 1752-1759.
P. LOCKWOOD, W. EWY, D. HERMANN, N. HOLFORD (2006), Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; An example in Alzheimer’s disease, “Pharmaceutical research”, 23, pp. 2050-2059.
J.M. MCGREE, J.A. ECCLESTON, S.B. DUFFULL (2009), Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations, “Journal of Pharmacokinetics and Pharmacodynamics”, 36, pp. 101-123.
H. MINAMI, K. KAWADA, Y. SASAKI, M. TAHARA, T. IGARASHI, K. ITOH, H. FUJII, T. SAEKI, K. OZAWA, H.
SATO (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice, “Cancer Science”, 100, pp. 144-149.
M.S. MOUKSASSI, J.F. MARIER, J. CYRAN, A.A. VINKS (2009), Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome, “Clinical Pharmacology & Therapeutics”, 86, pp. 667-671.
K. OGUNGBENRO, I. GUEORGUIEVA, O. MAJID, G. GRAHAM, L. AARONS (2007), Optimal Design for Multiresponse Pharmacokinetic-Pharmacodynamic Models - Dealing with Unbalanced Designs, “Journal of Pharmacokinetics and Pharmacodynamics”, 34, pp. 313-331.
J. O’ QUIGLEY (2002), Curve-free and model-based continual reassessment method designs, “Biometrics”, 58, pp. 245-249.
K. OZAWA, H. MINAMI, H. SATO (2009), Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binomial regression for febrile neutropenia, “Yakugaku Zasshi”, 129, pp. 749-757.
S. PIANTADOSI (2005), Clinical trials: a methodologic perspective, Wiley, Hoboken New Jersey.
G. PILLAI, R. GIESCHKE, T. GOGGIN, P. JACQMIN, R.C. SCHIMMER, J-L. STEIMER (2004), A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis, “British Journal of Clinical Pharmacology”, 58, pp. 618-631.
M. POSCH, P. BAUER, W. BRANNATH (2003), Issues in designing flexible trials, “Statistics in Medicine”, 22, pp. 953-969.
T.M. POST, J.I. FREIJER, J. DEJONGH, M. DANHOF (2005), Disease System Analysis: Basic Disease Progression Models in Degenerative Disease, “Pharmaceutical Research”, 22, pp. 1038-1049.
M. SALE (2004), Clinical Trial Simulation, in P.L. BONATE AND D.R. HOWARD (eds.), Pharmacokinetics in Drug Development: Clinical Study Design and Analysis (Volume 1), AAPS Press, Arlington.
T.J. SANTNER, B.J. WILLIAMS, W.I. NOTZ (2003), The Design and Analysis of Computer Experiments, Springer, New York.
R.G. SARGENT (2008), Verification and validation simulation models, in S. J. MASON, R. R. HILL, L.
MÖNCH, O. ROSE, T. JEFFERSON, J. W. FOWLER (eds.), Proceedings of the 2010 Winter Simulation Conference, Baltimore, USA, 5-8 Dec. 2010, (B. Johansson, S. Jain, J. Montoya-Torres, J. Hugan, and E. Yücesan, eds.) pp. 166-183.
S. SCHLESINGER, R.E. CROSBIE, R.E. GAGNÉ, G.S. INNIS, C.S. LALWANI, J. LOCH, R.J. SYLVESTER, R.D. WRIGHT, N. KHEIR, D. BARTOS (1979), Terminology for model credibility, “Simulation”, 32, pp. 103-104.
S. SENN (2007), Statistical issues in drug development, 2nd Edition, Wiley, Chichester, England; Hoboken, New Jersey.
MM. SHOUKRI (2004), Measures of Interobserver Agreement, Chapman & Hall/CRC, Boca Raton.
D.W. TAYLOR, E.G. BOSCH (1990), CTS: a clinical trias simulator, “Statistics in Medicine”, 9, pp. 787-801.
N. URBAN, C. DRESCHER, R. ETZIONI, C. COLBY (1997), Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, “Controlled Clinical Trials”, 18, pp. 251-270.
W. WANG, F. HUSAN, S.C. CHOW (1996), The impact of patient compliance on drug concentration profile in multiple doses, “Statistics in Medicine”, 15, pp. 659-669.
M.L. ZIERHUT, M.R. GASTONGUAY, S.W. MARTIN, P. VICINI, P.J. BEKKER, D. HOLLOWAY, P.T. LEESE, M.C. PETERSON (2008), Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women, “Journal of Pharmacokinetics and Pharmacodynamics”, 35, pp. 379-399.
How to Cite
Copyright (c) 2012 Statistica
This work is licensed under a Creative Commons Attribution 3.0 Unported License.